Zoliflodacin and gepotidacin make oral therapy viable again for urogenital gonorrhea, yet lower pharyngeal efficacy and weak resistance surveillance mean clinicians must adopt cautious, targeted use.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results